Core Viewpoint - The stock of Lanfeng Biochemical has experienced a significant surge, achieving three consecutive daily limit-ups, with a total increase of 33.21% during this period [1] Company Performance - The company reported a total revenue of 1.196 billion yuan for the first half of the year, representing a year-on-year growth of 40.89% [1] - The net profit for the same period was -44.78 million yuan, showing a year-on-year increase of 67.87% [1] - The basic earnings per share stood at -0.1193 yuan [1] Stock Market Activity - As of 9:25 AM, the stock price was 7.10 yuan, with a turnover rate of 1.58% and a trading volume of 4.1995 million shares, amounting to a transaction value of 29.82 million yuan [1] - The stock's total market capitalization reached 2.525 billion yuan, with a circulating market value of 1.883 billion yuan [1] - The stock was listed on the Dragon and Tiger List due to a cumulative price deviation of 20% over three trading days, with institutional net selling of 12.50 million yuan and a total net buying of 32.46 million yuan from brokerage seats [1] Recent Stock Performance - On September 23, the stock had a daily increase of 10.07% with a turnover rate of 18.17% and a net inflow of 29.47 million yuan [2] - On September 22, the stock rose by 9.94% with a turnover rate of 9.77% and a net inflow of 43.24 million yuan [2] - The stock showed fluctuations in previous days, including a slight increase of 0.38% on September 11 and a decrease of 1.86% on September 18 [3]

Group 1 - The core point of the article is that Lanfeng Biochemical has experienced a significant stock price increase, achieving a limit-up and a three-day consecutive rise [2] - Over the past three days, Lanfeng Biochemical's stock has accumulated a total increase of 33.21% [2]

Core Viewpoint - The company, Bluefeng Biochemical, announced that its stock price experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on September 22 and 23, 2025 [1] Summary by Relevant Sections - Stock Price Movement - The stock price of Bluefeng Biochemical showed a significant increase, with a cumulative rise of over 20% in the closing prices on September 22 and 23, 2025, indicating unusual trading activity [1] - Company Disclosure - The company confirmed that there are no corrections or supplements needed for previously disclosed information, and it has not identified any recent media reports that could have significantly impacted its stock price [1]

江苏蓝丰生物化工股份有限公司 关于公司股票交易异常波动的公告 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-056 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）股票交易价格于 2025 年 9 月 22 日、2025 年 9 月 23 日连续两个交易日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》等有关规定，属于股票交易异常波动的 情形。 5、除上述事项外，公司、控股股东和实际控制人不存在关于本公司应披露 1 而未披露的重大事项，或处于筹划阶段的重大事项。 6、经核查，公司控股股东、实际控制人在股票异动期间不存在买卖公司股 票的行为。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司对有关事项进行了核查，现就有关情况说 明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司未发现近期有公共媒体报道了可能或已经对本公司股票交易价格产 生较大影响的未公开重大信息。 3、公司目前经营情况正常，内外部经营环境未发生重大变化。 4、 ...

Core Viewpoint - The company, Bluefeng Biochemical, announced that its stock experienced an abnormal trading fluctuation with a cumulative closing price deviation exceeding 20% over two consecutive days, indicating potential market volatility [1] Group 1: Company Performance - The company confirmed that its operational status remains normal and that there have been no significant changes in the internal or external environment [1] - There are no undisclosed significant information that the company is required to disclose [1] Group 2: Stock Activity - The controlling shareholder and actual controller did not engage in any buying or selling of the company's stock during the period of abnormal trading [1] - The company has approved a restricted stock incentive plan related to its stock [1] Group 3: Investor Advisory - The company advises investors to pay attention to official disclosure channels and to be cautious of investment risks [1]

Group 1 - The core point of the article is that the company plans to invest 30 million RMB to establish a wholly-owned subsidiary in the renewable energy sector, specifically in photovoltaics, aligning with national 'dual carbon' policy goals [1] - The new subsidiary, Xiamen Lanfeng New Energy Technology Co., Ltd., will focus on renewable energy technology consulting, promotion services, and equipment research and development [1] - The company believes that this investment will positively impact its future development, enhancing core competitiveness and profitability [1]

Group 1 - The core point of the article is the announcement of Bluefeng Biochemical's restricted stock incentive plan, which involves granting 20.03 million shares to 72 individuals at a price of 2.64 yuan per share, representing 5.63% of the company's total share capital before the announcement [1] - The effective period of the restricted stock is up to 36 months from the completion of the registration of the stock grant [1] - As of the first half of 2025, Bluefeng Biochemical's revenue composition is 77.39% from photovoltaic products and 22.61% from pesticides [1] Group 2 - The current market capitalization of Bluefeng Biochemical is 1.9 billion yuan [1]

Group 1 - The core point of the article is that Jiangsu Lanfeng Biological Chemical Co., Ltd. has completed the execution of a lawsuit involving compensation claims from 200 investors, with a total compensation amount of approximately 23.738 million yuan [1][2] - The company has disclosed the details of the lawsuit, including the final judgment from Jiangsu High People's Court and the civil ruling and judgment from Nanjing Intermediate People's Court regarding the claims of 163 investors and 45 investors respectively [1][2] - The company has fulfilled all obligations related to the lawsuit, and all asset preservation and freezing measures have been lifted, with relevant bank accounts also unfrozen [1][2] Group 2 - The total compensation amount and related costs for the lawsuit are approximately 23.738 million yuan, which includes compensation for the lawsuit, litigation fees, case acceptance fees, execution fees, and overdue payment penalties [2] - The company will process the financial implications of the lawsuit according to relevant accounting standards, with the specific amount subject to audit results [2]

Group 1 - The company, Bluefeng Biochemical, held its 27th meeting of the 7th board of directors on September 19, 2025, via telecommunication to review proposals including external investment by subsidiaries [1] - For the first half of 2025, the company's revenue composition was 77.39% from photovoltaic business and 22.61% from pesticide business [1] - The current market capitalization of Bluefeng Biochemical is 1.9 billion yuan [2]

证券代码：002513 证券简称：蓝丰生化 江苏蓝丰生物化工股份有限公司 2025年限制性股票激励计划 （草案） 江苏蓝丰生物化工股份有限公司 二〇二五年九月 江苏蓝丰生物化工股份有限公司 2025年限制性股票激励计划（草案） 声 明 本公司及全体董事保证本激励计划及其摘要不存在虚假记载、误导性陈述或 重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或权益解除限售安排的，激励对象应当自相 关信息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激励 计划所获得的全部利益返还公司。 1 江苏蓝丰生物化工股份有限公司 2025年限制性股票激励计划（草案） 特别提示 一、本激励计划系依据《中华人民共和国公司法》、《中华人民共和国证券 法》、《上市公司股权激励管理办法》和其他有关法律、法规、规范性文件，以 及《江苏蓝丰生物化工股份有限公司章程》制订。 二、公司不存在《上市公司股权激励管理办法》第七条规定的不得实行股权 激励的情形。 三、本激励计划激励对象不存在《上市公司股权激励管理办法》第八 ...